Clinical trials: Pancreatic Cancer Borderline
Pancreatic Cancer Resectable, Pancreatic Cancer
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
This is an open-label, phase 1 clinical trial to evaluate the safety and preliminary efficacy of neoadjuvant chemoimmunotherapy (NAI, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel) followed by…
- Trial name
- ResQ108B-PANC (NCT07488884)
- Testing
- Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101)
- Sponsor
- ImmunityBio, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Divestment for Artery-involved Pancreatic Cancer
Pancreatic cancer is the most lethal malignancy of human being. Surgery is the only potential cure of pancreatic cancer. The invasion of major abdominal arteries is one of the most important factor restricting surgical…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Neoadjuvant Therapy, Borderline Resectable Pancreatic Cancer
- Trial name
- NCT03443921
- Testing
- Artery Divestment Technique, Nab-paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with…
- Trial name
- NCT01458717
- Testing
- Neoadjuvant chemoradiation, Upfront surgery
- Where
- 5 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- Seoul National University Hospital
CTCs, Pancreatic Cancer
EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases
The investigators conduct a single-center, prospective, observational study to explore the value of EUS-guided portal vein circulating tumor cells (PV-CTCs) and their subtypes combined with multi-omics tests in the early warning…
- Conditions
- CTCs, Pancreatic Cancer, Liver Metastases, Relapse
- Trial name
- NCT07448376
- Testing
- CTC
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huazhong University of Science and Technology
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival outcomes, even when treated with modern chemotherapy and radiation.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- PRISM-TAMP (NCT07477418)
- Testing
- Gemcitabine Delivered by Transarterial Microperfusion
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Vermont
Pancreatic Cancer
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy…
- Trial name
- NCT01661088
- Testing
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Adenocarcinoma of Pancreas
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year.
- Trial name
- NCT01359007
- Testing
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally…
- Trial name
- NCT06346808
- Testing
- Oncolytic virus Plus Anti-PD1 and Chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
This is a phase II study using the Bayesian platform design. There are three clinical stage groups of localized pancreatic cancer: resectable, borderline resectable, and locally advanced disease.
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04481204
- Testing
- Cisplatin, Fluorouracil, Gemcitabine
- Sponsor
- M.D. Anderson Cancer Center
Pancreas Cancer
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and…
- Trial name
- NCT05241249
- Testing
- Bethanechol, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Susan E. Bates
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Trial name
- NCT03600623
- Testing
- Folfirinox, Gemcitabine nab-Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Pancreatic Cancer
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03153410
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgical removal) or borderline…
- Trial name
- UVA-PC-PD101 (NCT02305186)
- Testing
- Pembrolizumab, Neoadjuvant Chemoradiation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Craig L Slingluff, Jr
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
- Trial name
- NCT06595160
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
The purpose of this study is to track outcomes and complications of patients at IUMC referred by physicians for EUS-guided pancreatic cyst ablation.
- Conditions
- Pancreatic Cyst, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Cystadenoma, Mucinous, Papillary Mucinous Cystadenoma, Borderline Malignancy
- Trial name
- NCT01643460
- Testing
- 98% Ethanol & Paclitaxel injection
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Adenocarcinoma
Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)
Pancreatic cancer is difficult to treat, and even in a situation where an operation can be performed to remove the cancer, the disease can unfortunately come back soon afterwards.
- Trial name
- PRICKLE (NCT02124369)
- Testing
- Abraxane, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- CCTU- Cancer Theme
Resectable Pancreatic Cancers
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
This research protocol will evaluate the feasibility of administering neoadjuvant gemcitabine and nab-paclitaxel with hypofractionated, image guided, intensity modulated radiotherapy (HIGRT) in resectable and borderline…
- Trial name
- NCT02318095
- Testing
- Gemcitabine/nab-Paclitaxel, Radiation therapy, Sugical resection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that may be…
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma
- Trial name
- NCT07619313
- Testing
- Biopsy Procedure, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Jonsson Comprehensive Cancer Center